Add this topic to your myFT Digest for news straight to your inbox
Investors are looking for more evidence that revenue will eventually turn into profits
Eyecare company’s plans to raise up to $840mn in second-largest listing of the year stymied by volatile markets
Drugmaker reaffirms full-year profit target as third-quarter beats expectations
Drugmaker gives up unit for nothing up front less than three years after paying $1bn
Drugmaker exceeds results expectations after accounting scandal
Shares climb in struggling US drugmaker after appointment
Tax gain helps Canadian drugmaker post first-quarter profit despite sliding sales
Ill-fated pharma bets and turmoil at AIG put pressure on hedge fund star
Pershing Square hedge fund lost more than 90% on investment of more than $3.2bn
Canadian drugmaker has been selling assets but retains net debt of more than $30bn
Canadian drugmaker will use deals with L’Oréal and Sanpower to pay down debt
Shares in Canadian drugmaker tumble after discussions with Japan’s Takeda collapse
Prosecutors say the men amassed tens of millions of dollars in secret payments
Papa suffers 26% slump in value of stock bought after he joined drugmaker in summer
Canadian drugmaker warns of ‘growth hole’ caused by loss of patent protection
Disposal of stomach-drug business would cut Quebec-based company’s heavy debt load
Group of enforcers would hold industry to account for ‘unjustified’ price increases
Dearth of ‘sell’ ratings before Tuesday’s collapse raises conflict questions
Valeant and Allergan chiefs signal end to ‘buy and raise’ deals
Shares plunge as politicians seek information related to sharp price hikes
International Edition